FDA Grants Priority Review to Olaparib, Bevacizumab Combination for Ovarian Cancer
The priority review was based on results from the phase III PAOLA-1 trial comparing the addition of olaparib to bevacizumab vs the standard-of-care alone. (Source: CancerNetwork)
Source: CancerNetwork - January 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer
WEDNESDAY, Dec. 18, 2019 -- Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2019 Category: Pharmaceuticals Source Type: news
Roche Says Tecentriq Cocktail Helps Liver Cancer Patients Live Longer Roche Says Tecentriq Cocktail Helps Liver Cancer Patients Live Longer
Swiss drugmaker Roche on Friday said its immunotherapy Tecentriq combined with its Avastin medicine helped people with the most common form of liver cancer to live longer than with an older drug from Germany ' s Bayer.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 26, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Roche says Tecentriq cocktail helps liver cancer patients live longer
Swiss drugmaker Roche on Friday said its immunotherapy Tecentriq combined with its Avastin medicine helped people with the most common form of liver cancer to live longer than with an older drug from Germany's Bayer. (Source: Reuters: Health)
Source: Reuters: Health - November 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer
Roche will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab). The data show statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - November 22, 2019 Category: Pharmaceuticals Source Type: news
Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer
Roche will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab). The data show statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 22, 2019 Category: Pharmaceuticals Source Type: news
Combination of immunotherapy and VEGF inhibitor improves survival in HCC
(European Society for Medical Oncology) Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2019 Category: Cancer & Oncology Source Type: news
FDA Accepts Biologics License Application for Bevacizumab Biosimilar
Samsung Bioepis announced that the FDA accepted a biologics license application for SB8, a biosimilar candidate for bevacizumab. (Source: CancerNetwork)
Source: CancerNetwork - November 21, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Questions Over Value of Bevacizumab in Many Cancers Questions Over Value of Bevacizumab in Many Cancers
The value of bevacizumab in the treatment of many cancers has been questioned, given that it has been approved mostly on the basis of progression-free, and not overall, survival benefits.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Roche pushes late-comer Tecentriq as new liver cancer option
Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals. (Source: Reuters: Health)
Source: Reuters: Health - October 21, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Roche ’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
Roche today announced that the Phase III IMbrave150 study, evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements i n overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. (Source: Roche Investor Update)
Source: Roche Investor Update - October 21, 2019 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
Roche today announced that the Phase III IMbrave150 study, evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements i n overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. (Source: Roche Media News)
Source: Roche Media News - October 21, 2019 Category: Pharmaceuticals Source Type: news
Nivolumab and Bevacizumab Combo Shows Activity in Ovarian Cancer
Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease. (Source: CancerNetwork)
Source: CancerNetwork - October 18, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Olaparib Plus Bevacizumab Prolongs Survival in Advanced Ovarian Cancer
Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 2, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
First-line Immunotherapy Still Elusive in Advanced Liver Cancer First-line Immunotherapy Still Elusive in Advanced Liver Cancer
First-line immunotherapy remains elusive for patients with hepatocellular carcinoma (HCC), but early results look good for a combination with bevacizumab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
